Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients with Prostate Cancer on Active Surveillance

Status

Recruiting

NCT ID

NCT03933670

This phase II trial studies the side how well hyperpolarized carbon C 13 pyruvate (HP C-13 pyruvate) magnetic resonance imaging (MRI) works in monitoring patients with prostate cancer on active surveillance who have not received treatment. Diagnostic procedures, such as MRI, may help visualize HP C-13 pyruvate uptake and breakdown in tumor cells.

Intervention

Hyperpolarized Carbon C 13 Pyruvate, MRI Ultrasound Fusion Guided Biopsy, Magnetic Resonance Spectroscopic Imaging

Condition

Prostate Adenocarcinoma, Prostate Cancer

Investigators

Ivan de Kouchkovsky, MD, Louise Magat,

See list of participating sites